Bacthera Q&A | Kisaco Research

Bacthera Q&A

Microbiome Connect: USA 2024
20-21 November, 2024

Would you please introduce Bacthera?

Bacthera is a strategic collaboration partner for the entire Live Biotherapeutic Product (LBP) CMC journey. As an independent operating joint venture between Chr. Hansen & Lonza, we bring together a highly experienced team in microbiology and pharma production. Bacthera enables the live biotherapeutic industry to thrive by offering a compelling set of manufacturing and development services across the entire LBP production life cycle. From early state development via clinical trial material manufacturing right through to commercial GMP manufacturing.

What kind of services do you offer?

We offer end-to-end development and manufacturing services for LBP’s from development to clinical and commercial scale in GMP quality. We also offer integrated drug substance and drug product development, validated assay development for product release, as well as handling oxygen-sensitive bacteria from drug substance to drug product in commercial capsules.

Whatever current needs and stages of CMC development, we tailor our live biotherapeutic product CDMO services to meet our customer expectations, enabling to go fast, de-risked and frictionless to the next step in the LBP journey.

What kind of strains do you work with?

Bacthera works with a variety of bacterial strains, including fastidious and oxygen sensitive anaerobes, risk group 1 and 2 strains, and GMO1 strains. These are strains such as Anaerostripes sp., Bacteriodes sp., Clostridium sp., Eubacterium sp., Faecalibacterium sp., Roseburia sp., etc.

What is the next milestone for Bacthera?

We are continuously working to become the leading CDMO in the LBP industry and have different major milestones ahead of us. We expect to be able to communicate one of these very soon at the Microbiome Connect conference in Boston.